ArticleCureus2025
GATA Binding Protein 3 as a Diagnostic Biomarker and Immune Infiltrates Regulator in Stomach Adenocarcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction GATA3 is a transcription factor that regulates cell differentiation, proliferation, and immune function. While it is well recognized as a diagnostic marker in breast and urothelial cancers, but in stomach adenocarcinoma (STAD) remains unclear. This study aimed to investigate the expression, clinical significance, promoter methylation, immune infiltration, and genetic alterations of GATA3 in STAD using comprehensive bioinformatics approaches. To our knowledge, this is the first study to systematically evaluate GATA3 across multiple datasets in the context of gastric cancer. Methods The analyses were conducted on publicly available datasets, including Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis (GEPIA), University of Alabama at Birmingham Cancer Data Analysis Portal (UALCAN), Kaplan-Meier plotter (KM Plotter), cBioPortal for Cancer Genomics, and Gene Expression Omnibus (GEO). Results Our results revealed that GATA3 is significantly upregulated across multiple cancer types, with the highest expression observed in STAD (p < 0.001). According to cancer stages I-IV, the expression increased in stages II-III but declined in stage IV, suggesting a role in tumor progression. However, survival analyses across several platforms consistently demonstrated no significant association between GATA3 expression and overall survival (p > 0.05). Immune infiltration analysis showed strong correlations between GATA3 expression and CD8+ T cells, CD4+ T cells, and macrophages (p < 0.0001), highlighting its potential involvement in shaping the tumor immune microenvironment. Interestingly, despite its upregulation, GATA3 exhibited elevated promoter methylation, suggesting additional regulatory mechanisms beyond epigenetics. Genetic alterations were rare (4%) and did not impact survival outcomes. Conclusion Collectively, these findings suggest that GATA3 is significantly upregulated in STAD and may serve as a novel diagnostic marker associated with immune infiltration. The study provides a foundation for future research exploring GATA3 as a potential target for diagnostic development and immunotherapy strategies in gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.